Search | Clinical Trials Finder

Conditions: PFIC1, PFIC2
Interventions: A4250 (odevixibat), Placebo; Drug
Lead sponsor: Albireo; Industry
Eligibility: 6 Months to 18 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more

Conditions: Biliary Obstruction Due to Common Bile Duct Stone, Malignant Bile Duct Obstruction
Interventions: Needle Knife Fistulotomy, standard biliary cannulation; Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Liver Cirrhosis, Biliary
Interventions: INT-747, Ursodeoxycholic Acid (URSO), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 13
States / cities: Gainesville, Florida • Miami, Florida • Boston, Massachusetts + 9 more

Conditions: Primary Biliary Cirrhosis
Interventions: rituximab; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Biliary Atresia, Alagille Syndrome, Alpha1 Anti-Trypsin Deficiency, Portal Hypertension, Liver Fibrosis, Cholestasis
Interventions: Liver Stiffness Measurement (LSM); Other
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: Up to 21 Years
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Short Bowel Syndrome
Interventions: elemental formula Elecare®, partially hydrolyzed formula; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Up to 1 Year
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Biliary Atresia
Interventions: Not listed
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: Up to 6 Months
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2029
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Primary Biliary Cirrhosis
Interventions: Pentoxifylline; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 76 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Primary Biliary Cholangitis
Interventions: Mindfulness Based Intervention; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Progressive Familial Intrahepatic Cholestasis (PFIC)
Interventions: Maralixibat, Placebo; Drug · Other
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 11
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 8 more

Conditions: Malnutrition, Child, Malnutrition, Essential Fatty Acid Deficiency (EFAD), Parenteral Nutrition Associated Cholestasis
Interventions: SMOFlipid® (lipid injectable emulsion); Drug
Lead sponsor: Fresenius Kabi; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 2 more

Conditions: Liver Failure, Liver Diseases, Alcoholic, Liver Diseases, Pain, Postoperative, Transplant; Failure, Liver, Liver Cirrhosis, Biliary
Interventions: BRIDGE device; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Primary Sclerosing Cholangitis (PSC)
Interventions: LB-P8 low-dose, LB-P8 high-dose, Placebo; Drug
Lead sponsor: LISCure Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Sacramento, California • Aurora, Colorado • Iowa City, Iowa + 4 more

Conditions: Primary Biliary Cholangitis (PBC)
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Alagille Syndrome
Interventions: Odevixibat, Placebo; Drug
Lead sponsor: Albireo; Industry
Eligibility: Not listed
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 5 more

Conditions: Alagille Syndrome
Interventions: Not listed
Lead sponsor: Ipsen; Industry
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Kansas City, Missouri + 6 more

Conditions: Cholestasis, Red Cell Membrane and Enzyme Abnormalities
Interventions: ektacytometry of red blood cells; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Year and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Progressive Familial Intrahepatic Cholestasis (PFIC)
Interventions: LUM001 (Maralixibat); Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 12 Months to 18 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 5
States / cities: Los Angeles, California • Aurora, Colorado • Cincinnati, Ohio + 2 more

Conditions: Cholestatic Liver Disease
Interventions: Saroglitazar Magnesium 1 mg; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Cholestatic Pruritus
Interventions: CR845 1.0 mg, Placebo; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 14
States / cities: Coronado, California • Rialto, California • San Francisco, California + 10 more

Conditions: Primary Biliary Cholangitis
Interventions: Saroglitazar magnesium 1 mg, Placebo; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 3
States / cities: Marietta, Georgia • Indianapolis, Indiana • Houston, Texas

Conditions: Cholestasis
Interventions: Omegaven; Drug
Lead sponsor: Carle Foundation Hospital; Other
Eligibility: 14 Days to 4 Months
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Primary Biliary Cirrhosis (PBC)
Interventions: Placebo Comparator, Experimental: Seladelpar 50 mg, Experimental: Seladelpar / MBX-8025 200 mg; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 21
States / cities: Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 16 more

Conditions: Cholestasis, Short Bowel Syndrome
Interventions: Omegaven; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 21 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2

Needle-Knife Fistulotomy Vs. Standard Cannulation Trial

Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

Initial Study of Rituximab to Treat Primary Biliary Cirrhosis

FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)

Elemental Formula in Neonates Post Small Bowel Resection: Improved Weaning From Total Parenteral Nutrition?

A Prospective Database of Infants With Cholestasis

Pentoxifylline for Primary Biliary Cirrhosis

Mindfulness - Based Intervention in the Treatment of Fatigue in Patients With Primary Biliary Cholangitis

A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)

Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients

BRIDGE Device for Post-operative Pain Control

A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

Using Digital Health Technology to Monitor Patients With Primary Biliary Cholangitis (PBC)

Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome

A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

Osmotic Fragility in Red Blood Cells of Pediatric Patients With Cholestatic Liver Disease

Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes

Omegaven® as Parenteral Nutrition

Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)

Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease